Triangle firm slaps feds with lawsuit over delayed product launch Morrisville firm stunned by FDA setback, vows 'quick action ...

The fresh funds provided by the European Innovation Council will help the Cambridge-based company overcome technical barriers ...

Some promising factors include: FDA approvals for new drugs Capex spending and VC investment in biotech firms AI-assisted breakthroughs in drug development and manufacturing An aging population ...

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other ...

The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share. The biotechnology firm posted revenue of $7,000 in the period.

a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b ...

Kennedy Jr.) signals potential changes in FDA priorities and how the agency engages with biotech firms. The following article analyzes strategic and operational implications for biotech companies ...

“That paranoia has gotten wrapped into mRNA as a word,” says Jeff Coller, an RNA biologist at Johns Hopkins University in Baltimore, Maryland, who is also involved in several small biotech firms.

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% ...

The Massachusetts-based biotech firm plans to set up shop in an undisclosed office in South San Francisco after its $1.5 billion buyout last year of locally based Human Immunology Biosciences ...

Share traders in Shanghai joke that Cambricon, a local firm, not only offers a substitute for Nvidia’s processors, but for its stock, too. Although the Chinese semiconductor firm is worth but a ...

Microsoft indefinitely postponed a $1 billion data center expansion, much of which was planned for New Albany, biotech firm AmplifyBio shut down completely earlier this year, including its New ...